Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-06-12 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin ha marcato CE il proprio test molecolare Simplexa™ Congenital CMV Direct
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin, dated June 12, 2020, regarding the CE marking of a new molecular test (Simplexa™ Congenital CMV Direct). The metadata indicates it was received as 'Informazione Regolamentata' (Regulated Information) with the Tipologia 'REGEM'. The content describes a significant product development and its implications, which is a type of corporate news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), but rather a specific announcement of a regulatory/product milestone, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). Although it contains product information, it is structured as a formal regulatory disclosure. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-financial, regulatory milestone announcement that isn't covered by other specific codes like DIRS, DIV, or CAP. The document length is moderate (4654 chars), but the content is a direct announcement, not a link to a larger report, so RPA is less likely than RNS for this type of regulatory news.
2020-06-12 Italian
Shareholders' Meeting June 10, 2020
AGM Information Classification · 98% confidence The document explicitly states in the 'Oggetto' (Subject) field: 'Shareholders' Meeting June 10, 2020'. The body details resolutions passed by the 'ORDINARY SHAREHOLDERS' MEETING', including the approval of statutory financial statements, dividend distribution, approval of the Remuneration Policy, and the establishment of a Stock Options Plan. These are typical outcomes and announcements following an Annual General Meeting (AGM). Since the document summarizes the results and decisions made during the meeting, it aligns best with the AGM Information category (AGM-R), which covers presentations and materials shared during the AGM.
2020-06-10 English
Assemblea degli Azionisti 10 giugno 2020
AGM Information Classification · 98% confidence The document is an official communication dated June 10, 2020, with the subject line 'Assemblea degli Azionisti 10 giugno 2020' (Shareholders' Meeting June 10, 2020). The text details the resolutions passed by the Ordinary Shareholders' Meeting, including the approval of the 2019 Financial Statements, dividend distribution, remuneration policy, and the establishment of a new stock option plan and authorization for share buybacks. Since the document summarizes the key outcomes and resolutions of the Annual General Meeting (AGM), it directly relates to the proceedings of that meeting. Although it mentions financial results (which could suggest ER or IR), the primary context is the formal meeting and its decisions. This aligns best with 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM.
2020-06-10 Italian
The LIAISON® SARS-CoV-2 S1 S2 IgG test receives the approval from ANVISA in Brazil
Regulatory Filings Classification · 98% confidence The document is a formal announcement from DiaSorin dated June 3, 2020, regarding receiving approval from ANVISA (Brazilian Health Regulatory Agency) for the commercialization of their LIAISON® SARS-CoV-2 S1/S2 IgG test in Brazil. The metadata indicates the filing type is 'REGEM' (likely a local regulatory filing type) and the document is short, containing an announcement ('Oggetto') and stating 'Vedi allegato' (See attachment), suggesting it is an initial disclosure of a material event rather than a comprehensive periodic report (like 10-K or IR). Since it announces a specific regulatory/commercial event (product approval) and doesn't fit the definitions for earnings (ER), capital changes (CAP), or director dealings (DIRS), it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous, material, non-periodic announcement, or potentially a Regulatory Filing (RNS) if the specific nature of the approval announcement doesn't map cleanly elsewhere. Given the context of regulatory approval for a diagnostic test, RNS is the most appropriate general regulatory announcement category.
2020-06-03 English
Il test sierologico LIAISON® SARS-CoV-2 S1 S2 IgG riceve l'approvazione da ANVISA per il mercato brasiliano
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin, dated June 3, 2020, regarding regulatory approval received from ANVISA (the Brazilian health regulatory agency) for their LIAISON® SARS-CoV-2 S1/S2 IgG serological test. The document details the approval, the test's specifications, and previous approvals in the US and Canada. The structure, including 'Oggetto' (Subject) and 'Testo del comunicato' (Body of the communication), along with the metadata indicating 'Tipologia: REGEM' (Regulated Information), strongly suggests this is a mandatory disclosure of a significant event to the market. Since it is an announcement of a specific event (regulatory approval for a product) that doesn't fit neatly into earnings (ER), capital changes (CAP), or director dealings (DIRS), it falls best under the general category for regulatory announcements that are not standard periodic reports. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a specific, non-periodic regulatory event disclosure that isn't covered by other specific codes like 10-K or ER.
2020-06-03 Portuguese
Communication voting rights amount
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication from DiaSorin S.p.A. dated June 2, 2020, titled 'COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS pursuant to Article 85-bis, paragraph 4-bis, of Consob Regulation no. 11971/1999'. It explicitly details the total number of shares and the corresponding total number of voting rights as of a specific record date (June 1, 2020), distinguishing between ordinary shares with and without increased voting rights. This content directly relates to the official results or status of shareholder voting rights and capital structure related to voting power. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (Code: DVA). Although it is a communication, the subject matter is specific enough to warrant DVA over the general 'RPA' or 'RNS'. The document length is short (3013 chars), but the content is the actual declaration, not just an announcement that the declaration is attached.
2020-06-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.